Monarch Partners Asset Management LLC Raises Holdings in Cryolife Inc (NYSE:CRY)

Monarch Partners Asset Management LLC grew its position in shares of Cryolife Inc (NYSE:CRY) by 13.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 257,928 shares of the medical equipment provider’s stock after purchasing an additional 30,190 shares during the quarter. Monarch Partners Asset Management LLC owned approximately 0.69% of Cryolife worth $7,003,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of CRY. Panagora Asset Management Inc. purchased a new position in shares of Cryolife during the second quarter worth about $32,000. Bank of Montreal Can grew its holdings in shares of Cryolife by 238.6% during the second quarter. Bank of Montreal Can now owns 5,143 shares of the medical equipment provider’s stock worth $154,000 after purchasing an additional 3,624 shares during the last quarter. Smith Capital Management Inc. AR ADV purchased a new position in shares of Cryolife during the second quarter worth about $202,000. Paloma Partners Management Co purchased a new position in shares of Cryolife during the second quarter worth about $269,000. Finally, Laurion Capital Management LP purchased a new position in shares of Cryolife during the second quarter worth about $276,000. 70.31% of the stock is currently owned by institutional investors.

Shares of NYSE CRY traded down $0.02 during midday trading on Friday, reaching $23.25. 162,832 shares of the company were exchanged, compared to its average volume of 198,355. The company has a current ratio of 5.03, a quick ratio of 3.82 and a debt-to-equity ratio of 0.83. Cryolife Inc has a 1 year low of $20.76 and a 1 year high of $33.00. The stock has a fifty day simple moving average of $24.85 and a 200 day simple moving average of $27.92. The stock has a market cap of $886.96 million, a P/E ratio of 89.42, a PEG ratio of 42.23 and a beta of 0.61.

Cryolife (NYSE:CRY) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $0.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.02. Cryolife had a return on equity of 3.50% and a net margin of 0.24%. The firm had revenue of $67.90 million for the quarter, compared to analyst estimates of $68.28 million. During the same quarter last year, the company posted $0.08 earnings per share. The business’s revenue was up 5.1% on a year-over-year basis. As a group, analysts forecast that Cryolife Inc will post 0.28 earnings per share for the current year.

A number of research firms recently issued reports on CRY. Oppenheimer began coverage on Cryolife in a report on Tuesday, October 22nd. They set an “outperform” rating and a $34.00 price target on the stock. Canaccord Genuity set a $35.00 price target on Cryolife and gave the stock a “buy” rating in a report on Wednesday, July 31st. ValuEngine lowered Cryolife from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 1st. Finally, Zacks Investment Research lowered Cryolife from a “buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $31.53.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

See Also: Understanding the Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply